// App-Quantinova.ai

: WU-NK-101, an enhanced memory natural killer (NK) cell therapy, with cetuximab (Ctx) for the treatment of advanced colorectal cancer (CRC).

Researchers

Presenter

  • John Muth

Principal Investigators

  • Alexander Hamil

  • Lena Luukkonen

  • Brunda Tumala

  • Alun Carter

  • Kristann Magee

  • Paula Comune Pennacchi

  • Daniel Primo

  • Michael A. Kiebish

  • David Boocock

  • Jayakumar Vadakekolathu

  • Vincent Petit

  • Jan E. Baughman

  • Nupur Bhatnagar

  • Matthew Cooper

  • Sergio Rutella

  • Melissa Berrien-Elliot

  • Jan Davidson-Moncada

  • Todd A. Fehniger

Medical Centers

  • Quest Clinical Research, San Francisco, CA

  • ViviaBiotech S.L., Tres Cantos, Spain

  • Berg LLC, Framingham, MA

  • Wugen, St. Louis, MO

  • Wugen, St. Louis, MO

  • Nottingham Trent University, Nottingham, United Kingdom

  • Metafora Biosystems, Paris, France

  • Wugen, St. Louis, MO

  • Washington University School of Medicine, St. Louis, MO

  • Wugen, St. Louis, MO

  • Washington University, St Louis, MO

Locations

  • Spain

  • United Kingdom

  • France

  • United States

Companies

  • BERG, LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

  • Erbitux

  • NK 101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved